Opportunities for Capricor Therapeutics Investors to Lead Securities Fraud Class Action Lawsuit

Capricor Therapeutics Shareholder Action

Investors who faced losses with Capricor Therapeutics, Inc. (ticker: CAPR) have recently been offered the opportunity to lead a class-action lawsuit regarding allegations of securities fraud. The law firm Glancy Prongay Wolke & Rotter LLP announced this possibility for shareholders who have suffered financial damage due to misleading statements made by the company between December 17, 2025, and July 26, 2026.

The Allegations

The lawsuit arises from the claims that Capricor Therapeutics provided materially false and misleading statements about their company operations and future prospects. Notably, it is alleged that the company did not adequately disclose significant changes made to their pre-specified statistical analysis plan for analyzing clinical data related to their product, Deramiocel. Furthermore, it’s stated that the FDA had not approved these changes prior to the company resubmitting the Biologics License Application (BLA) for Deramiocel, compromising substantial evidence of the drug’s effectiveness.

The claims suggest a considerable risk that regulatory approval for Deramiocel, aimed at treating Duchenne muscular dystrophy, is now jeopardized, which heavily contradicts the prior optimistic public statements by the company's officials. Investors who believe they have been misled and lost money as a result are urged to consider their legal options.

How to Participate

To lead the class action lawsuit, investors must take action before the deadline on September 28, 2026. Those who wish to represent fellow shareholders need to file their motions with the court within this timeframe. Potential plaintiffs can learn more about their rights and the legal process by reaching out to Glancy Prongay Wolke & Rotter LLP.

The firm reports a strong track record in representing investors in various securities litigations and claims that they have achieved significant recoveries for clients in similar cases. Glancy Prongay Wolke & Rotter LLP has notably been recognized in the legal field, being named one of the Securities Groups of the Year by Law360.

Next Steps for Shareholders

Investors should consider acting quickly to safeguard their rights. By initiating or joining the lawsuit, shareholders can potentially recover any losses incurred during the investment period. If investors opt not to take any action, they will still hold their status as absent class members when the court seeks to certify the class.

For those interested in pursuing claims, Glancy Prongay is prepared to guide them through the process. Interested parties can reach out via email or phone for more information and assistance.

Given the legal complexities involved in such cases, seeking advice from qualified counsel may also be beneficial to navigate the class action landscape effectively. The path to recovering losses in securities fraud cases can be intricate, yet with timely action, investors have a chance to make their voices heard.